00
005250.KO Green Cross
- Market cap
- KRW 438B
- P/E
- -
- P/B
- 0.50x
- ROE
- -3.6%
- Dividend yield
- 7.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 005250.KO undervalued?
Graham numberThe Graham number of Green Cross cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Green Cross fundamental analysis
No fundamental analysis for Green Cross yet.
Green Cross stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Green Cross
GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purp…
Full company profileGreen Cross financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Green Cross annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.35T | 1.46T | 1.55T | 1.52T | 1.72T | 1.84T | 2.08T | 2.06T | 2.20T | 2.45T | 2.26T |
| Gross Profit | 392B | 412B | 406B | 427B | 530B | 629B | 698B | 604B | 620B | 683B | 653B |
| Operating Income | 98.7B | 111B | 48.7B | 27.3B | 70.8B | 86.3B | 71.2B | -16.4B | -10.7B | 36.5B | 19.4B |
| EBITDA | - | 151B | 108B | 61.6B | 185B | 270B | 145B | 66.8B | 213B | 126B | 165B |
| Net Income | 47.2B | 43.4B | 18.5B | 2.96B | 171B | 55.3B | 32.8B | -54.1B | 24.0B | -69.5B | -31.5B |
| EPS | - | 965 | 411 | 66 | 3,805 | 1,230 | 730 | -1,205 | 535 | -1,539 | -701 |
| Balance Sheet | |||||||||||
| Total Assets | 2.25T | 2.56T | 2.63T | 2.77T | 3.24T | 3.50T | 3.59T | 3.74T | 3.67T | 4.07T | 4.18T |
| Total Liabilities | 872B | 1.12T | 1.18T | 1.27T | 1.57T | 1.59T | 1.63T | 1.86T | 1.82T | 2.31T | 2.44T |
| Shareholders' Equity | 772B | 813B | 804B | 813B | 919B | 1.03T | 1.04T | 980B | 994B | 901B | 868B |
| Cash & Short-term Investments | 114B | 269B | 251B | 176B | 448B | 336B | 209B | 175B | 77.3B | 79.7B | 85.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -805M | 144B | 37.6B | 7.65B | 35.8B | 104B | 97.2B | -39.7B | -89.9B | 24.3B | -119B |
| Capital Expenditure | 179B | 196B | 118B | 139B | 108B | 117B | 127B | 133B | 57.7B | 150B | 142B |
| Free Cash Flow | - | -66.6B | -110B | -157B | -97.6B | -38.1B | -30.0B | -172B | -148B | -126B | -260B |
| Ratios | |||||||||||
| ROE | 6.1% | 5.3% | 2.3% | 0.4% | 18.6% | 5.4% | 3.2% | -5.5% | 2.4% | -7.7% | -3.6% |
| ROA | 2.1% | 1.7% | 0.7% | 0.1% | 5.3% | 1.6% | 0.9% | -1.4% | 0.7% | -1.7% | -0.8% |
| Net Profit Margin | 3.5% | 3.0% | 1.2% | 0.2% | 9.9% | 3.0% | 1.6% | -2.6% | 1.1% | -2.8% | -1.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Green Cross dividends
- Dividend yield
- 7.58%
- Forward dividend
- 300.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 33.2B | 735 | - |
| 2024 | KRW 25.4B | 566 | 105.9% |
| 2023 | KRW 29.9B | 666 | - |
| 2022 | KRW 31.5B | 701 | 96.0% |
| 2021 | KRW 32.2B | 717 | 58.3% |
| 2020 | KRW 21.5B | 478 | 12.6% |
| 2019 | KRW 18.3B | 407 | 618.1% |
| 2018 | KRW 22.1B | 492 | 119.7% |
| 2017 | KRW 22.1B | 491 | 50.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Apr 18, 2011.
Who owns Green Cross
- Insiders 49.83%
- Institutions 9.26%
- Public & others 40.91%
- Shares outstanding 45.0M
- Free float 25.2M
Green Cross company profile
- Company name
- Green Cross
- Ticker
- 005250.KO
- ISIN
- KR7005250006
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Fiscal year end
- December
- Address
- 107, Ihyeon-ro 30beon-gil, Yongin-Si, South Korea
- Phone
- 82 3 1260 9300
- Website
- gccorp.com
About Green Cross
GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille's syndrome. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies, and clinical trials. Additionally, the company provides personalized nutrition injections. The company was formerly known as Green Cross Holdings Corporation and changed its name to GC Corp. in April 2026. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea.
Green Cross management
1- Mr. Yong-Jun HuhCEO & Director · born 1974